Burden of disease associated with a COPD eosinophilic phenotype
Received 13 April 2018
Accepted for publication 29 June 2018
Published 13 August 2018 Volume 2018:13 Pages 2425—2433
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 3
Editor who approved publication: Dr Richard Russell
Hector Ortega,1 Jean-Pierre Llanos,2 Marie-Hélène Lafeuille,3 Guillaume Germain,3 Mei Sheng Duh,4 Christopher F Bell,2 Susan R Sama,5 Beth Hahn2
1Respiratory, US Medical Affairs, GSK, La Jolla, CA, USA; 2Respiratory, US Medical Affairs, GSK Research Triangle Park, NC, USA; 3Groupe d’analyse, Ltée, Montréal, QC, Canada; 4Analysis Group, Inc., Boston, MA, USA; 5Research Department, Reliant Medical Group, Worcester, MA, USA
Purpose: Based on blood and sputum samples, up to 40% of patients with COPD have eosinophilic inflammation; however, there is little epidemiology data characterizing the health care burden within this sub-population. Given that COPD-attributable medical costs in the USA are predicted to approach $50 billion by 2020, we analyzed the effect of blood eosinophil counts and exacerbations on health care resource utilization and costs.
Patients and methods: This cross-sectional study used electronic medical records and insurance claims data from the Reliant Medical Group (January 2011–December 2015). Eligible patients were ≥40 years of age, continuously enrolled during the year of interest (2012, 2013, 2014, or 2015), had ≥1 COPD-related code in the preceding year, and documented maintenance therapy use. Patients with ≥1 blood eosinophil count recorded were stratified into 2 cohorts: <150 cells/μL and ≥150 cells/μL. Endpoints included demographics, clinical characteristics, health care resource utilization, and costs. The impact of blood eosinophil count and exacerbation patterns on health care resource utilization and costs was assessed with multivariate analyses.
Results: On average, 2,832 eligible patients were enrolled annually, of whom ~28% had ≥1 eosinophil count recorded during the year. The ≥150 cells/μL cohort had numerically higher all-cause and COPD-related health care resource utilization and cost each year compared with the <150 cells/μL cohort, but varied by service and year. Among patients with exacerbations, the ≥150 cells/μL cohort exhibited significantly higher COPD-related costs compared with the <150 cells/μL cohort.
Conclusion: Blood eosinophil counts may be a useful biomarker for burden of disease in a subgroup of patients with COPD.
Keywords: COPD triple therapy, COPD exacerbations, eosinophils, health care resource utilization
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]